Patrick Daly

Patrick Daly is a contributing writer for Cancer Nursing Today. He is an assistant editor for DocWire News with several years of experience in producing multimedia content for B2B and B2C audiences in the financial and health care industries.

Articles by Patrick Daly

Patrick DalyConferences | September 15, 2023
Patients with ibrutinib dose reductions after AEs had longer treatments and similar outcomes to those without reductions.
Read More
Patrick DalyConferences | September 15, 2023
Patients with CLL who relapsed after HSCT and then received venetoclax achieved outcomes consistent with trial data.
Patrick DalyConferences | September 15, 2023
The rituximab, fludarabine, and cyclophosphamide regimen appeared to be most effective for overall survival and response.
Patrick DalyConferences | September 15, 2023
Data suggest patients with CLL are more anxious when receiving intravenous versus oral treatment.
Patrick DalyGVHD | December 22, 2022
Different radiotherapy doses in allogeneic HCT conditioning had no apparent impact on the rate of acute GVHD.
Patrick DalyGVHD | December 22, 2022
Authors observed that ocular graft-versus-host disease usually developed after a history of systemic disease.
Patrick DalyGVHD | December 22, 2022
A study found fecal microbiome dysbiosis accompanied the onset of gastrointestinal graft-versus-host disease.
Patrick DalyGVHD | December 22, 2022
BCG vaccination at birth was associated with increased risk of acute GVHD after HCT in pediatric patients.
Patrick DalyGVHD | December 20, 2022
Vitamin D Deficiency before HSCT was associated with increased rate of aGVHD in patients with thalassemia major.
Patrick DalyGVHD | December 20, 2022
Higher tacrolimus pharmacokinetic variability had a greater risk of aGVHD that rose alongside concentration variability.
Patrick DalyGVHD | December 20, 2022
defibrotide added to standard-of-care graft-versus-host disease prophylaxis appeared to improve the rate of acute GVHD.
Patrick DalyGVHD | December 20, 2022
FEV1/FVC and PEF/pred could identify patients with higher risk for pulmonary chronic graft-versus-host disease before HSCT.
Patrick DalyGVHD | December 7, 2022
Real-world data showed that ruxolitinib was effective in a population of heavily pretreated patients with cGVHD.
Patrick DalyGVHD | December 7, 2022
Vedolizumab was safe and effective for GI aGVHD treatment, although its efficacy as GVHD prophylaxis was unclear.
Patrick DalyGVHD | November 23, 2022
Patients reported significant symptom burden and daily activity impairments in the online Living With Chronic GVHD Patient Su
Patrick DalyGVHD | November 23, 2022
Researchers found bronchiolitis obliterans syndrome was less frequent in HCT with HID donors compared with MSD and MUDs.
Patrick DalyGVHD | November 23, 2022
Researchers found sVCAM-1 levels were higher pre- and post-HCT in patients who developed severe aGVHD.
Patrick DalyGVHD | November 23, 2022
Extracellular vesicles at engraftment in hematopoietic cell transplantation may be a feasible biomarker for acute GVHD.
Patrick DalyGVHD | November 16, 2022
Patients with steroid-refractory acute graft-versus-host disease who received ECP had better survival than those who did not.
Patrick DalyGVHD | November 16, 2022
Investigators found greater risk for severe acute graft-versus-host disease in omitting the day 11 dose of mini-methotrexate.